ATRC Stock Forecast 2025-2026
Distance to ATRC Price Targets
ATRC Price Momentum
10 Quality Stocks Worth Considering Now
Researching AtriCure (ATRC) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ATRC and similar high-potential opportunities.
Latest ATRC Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, ATRC has a bullish consensus with a median price target of $51.00 (ranging from $45.00 to $66.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $34.90, the median forecast implies a 46.1% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from William Plovanic at Canaccord Genuity, projecting a 89.1% upside. Conversely, the most conservative target is provided by Suraj Kalia at Oppenheimer, suggesting a 28.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ATRC Analyst Ratings
ATRC Price Target Range
Latest ATRC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ATRC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 21, 2025 | Needham | Mike Matson | Buy | Reiterates | $51.00 |
| Feb 13, 2025 | JMP Securities | Daniel Stauder | Market Outperform | Reiterates | $60.00 |
| Feb 13, 2025 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $50.00 |
| Feb 13, 2025 | Oppenheimer | Suraj Kalia | Outperform | Maintains | $45.00 |
| Feb 13, 2025 | Stifel | Rick Wise | Buy | Maintains | $48.00 |
| Feb 13, 2025 | Needham | Mike Matson | Buy | Reiterates | $51.00 |
| Feb 13, 2025 | Canaccord Genuity | William Plovanic | Buy | Maintains | $66.00 |
| Feb 11, 2025 | JP Morgan | Lilia-Celine Lozada | Overweight | Maintains | $51.00 |
| Feb 10, 2025 | JMP Securities | Daniel Stauder | Market Outperform | Reiterates | $60.00 |
| Jan 22, 2025 | Needham | Mike Matson | Buy | Maintains | $51.00 |
| Jan 13, 2025 | Needham | Mike Matson | Buy | Reiterates | $40.00 |
| Dec 17, 2024 | JP Morgan | Lilia-Celine Lozada | Overweight | Assumes | $40.00 |
| Dec 9, 2024 | Canaccord Genuity | William Plovanic | Buy | Maintains | $61.00 |
| Oct 30, 2024 | Needham | Mike Matson | Buy | Maintains | $40.00 |
| Oct 30, 2024 | Oppenheimer | Suraj Kalia | Outperform | Maintains | $36.00 |
| Oct 30, 2024 | UBS | Danielle Antalffy | Buy | Maintains | $40.00 |
| Oct 30, 2024 | JP Morgan | Robbie Marcus | Overweight | Maintains | $40.00 |
| Oct 30, 2024 | Canaccord Genuity | William Plovanic | Buy | Maintains | $53.00 |
| Jul 31, 2024 | JP Morgan | Robbie Marcus | Overweight | Maintains | $30.00 |
| Jul 31, 2024 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $40.00 |
AtriCure Inc. (ATRC) Competitors
The following stocks are similar to AtriCure based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
AtriCure Inc. (ATRC) Financial Data
AtriCure Inc. has a market capitalization of $1.72B with a P/E ratio of 0.0x. The company generates $465.31M in trailing twelve-month revenue with a -9.6% profit margin.
Revenue growth is +16.6% quarter-over-quarter, while maintaining an operating margin of -11.7% and return on equity of -9.6%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
AtriCure Inc. (ATRC) Business Model
About AtriCure Inc.
Develops medical devices for cardiac care.
AtriCure generates revenue by creating and selling innovative medical devices that focus on treating atrial fibrillation and related heart conditions. Their product offerings include surgical tools and minimally invasive systems, catering to cardiac surgeons and electrophysiologists, which enhances the effectiveness of cardiac procedures.
Founded in 2000 and based in Mason, Ohio, AtriCure is a significant player in the medical device industry, addressing complex cardiac conditions that impact millions of people worldwide. The company's commitment to advancing surgical innovations plays a vital role in improving patient safety and treatment outcomes in the cardiovascular field.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
1,300
CEO
Mr. Michael H. Carrel
Country
United States
IPO Year
2005
Website
www.atricure.comAtriCure Inc. (ATRC) Latest News & Analysis
AtriCure, Inc. (Nasdaq: ATRC) will host an Analyst & Investor Day on March 26, 2025, showcasing its product portfolio and pipeline innovations.
AtriCure's Analyst & Investor Day announcement signals potential growth and innovation, which could influence stock performance and investor sentiment regarding future earnings.
AtriCure, Inc. (NASDAQ: ATRC) will host its Q4 2024 earnings conference call on February 12, 2025, at 4:30 PM ET, featuring key executives and various analysts.
AtriCure's upcoming earnings call will provide insights into its financial performance and future outlook, affecting stock valuation and investor sentiment.
AtriCure, Inc. (Nasdaq: ATRC) reported strong Q4 2024 and full-year results, highlighting growth, improved profitability, and key product launches in surgical treatments for atrial fibrillation.
AtriCure's strong financial results and product launches signal growth and profitability, which could enhance investor confidence and potentially boost stock performance.
AtriCure (ATRC) reported a quarterly loss of $0.08 per share, better than the estimated loss of $0.15, and an improvement from a loss of $0.21 per share a year prior.
AtriCure's smaller-than-expected loss indicates improving financial performance, which may boost investor confidence and positively influence stock price.
AtriCure's Q4 2024 performance metrics are being analyzed against Wall Street estimates and year-ago figures for investor insights.
AtriCure's performance against Wall Street estimates and prior year metrics can indicate growth potential and market confidence, influencing stock valuation and investment decisions.
AtriCure (ATRC) has been upgraded to a Zacks Rank #2 (Buy), indicating growing optimism about its earnings prospects.
AtriCure's upgrade to Zacks Rank #2 signals strong earnings potential, suggesting positive market sentiment and potential stock price appreciation, attracting investor interest.
Frequently Asked Questions About ATRC Stock
What is AtriCure Inc.'s (ATRC) stock forecast for 2025?
Based on our analysis of 13 Wall Street analysts, AtriCure Inc. (ATRC) has a median price target of $51.00. The highest price target is $66.00 and the lowest is $45.00.
Is ATRC stock a good investment in 2025?
According to current analyst ratings, ATRC has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $34.90. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ATRC stock?
Wall Street analysts predict ATRC stock could reach $51.00 in the next 12 months. This represents a 46.1% increase from the current price of $34.90. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is AtriCure Inc.'s business model?
AtriCure generates revenue by creating and selling innovative medical devices that focus on treating atrial fibrillation and related heart conditions. Their product offerings include surgical tools and minimally invasive systems, catering to cardiac surgeons and electrophysiologists, which enhances the effectiveness of cardiac procedures.
What is the highest forecasted price for ATRC AtriCure Inc.?
The highest price target for ATRC is $66.00 from William Plovanic at Canaccord Genuity, which represents a 89.1% increase from the current price of $34.90.
What is the lowest forecasted price for ATRC AtriCure Inc.?
The lowest price target for ATRC is $45.00 from Suraj Kalia at Oppenheimer, which represents a 28.9% increase from the current price of $34.90.
What is the overall ATRC consensus from analysts for AtriCure Inc.?
The overall analyst consensus for ATRC is bullish. Out of 13 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $51.00.
How accurate are ATRC stock price projections?
Stock price projections, including those for AtriCure Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
